Journal
SPECIAL ISSUE: THE YEAR IN NEUROLOGY AND PSYCHIATRY
Volume 1366, Issue -, Pages 76-89Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.13048
Keywords
bipolar disorder; clinical; genetics; mood; therapy
Categories
Funding
- National Institute for Health Research [NF-SI-0513-10010] Funding Source: researchfish
- Medical Research Council Funding Source: Medline
- Wellcome Trust [104571] Funding Source: Medline
Ask authors/readers for more resources
All psychiatric disorders have suffered from a dearth of truly novel pharmacological interventions. In bipolar disorder, lithium remains a mainstay of treatment, six decades since its effects were serendipitously discovered. The lack of progress reflects several factors, including ignorance of the disorder's pathophysiology and the complexities of the clinical phenotype. After reviewing the current status, we discuss some ways forward. First, we highlight the need for a richer characterization of the clinical profile, facilitated by novel devices and new forms of data capture and analysis; such data are already promoting a reevaluation of the phenotype, with an emphasis on mood instability rather than on discrete clinical episodes. Second, experimental medicine can provide early indications of target engagement and therapeutic response, reducing the time, cost, and risk involved in evaluating potential mood stabilizers. Third, genomic data can inform target identification and validation, such as the increasing evidence for involvement of calcium channel genes in bipolar disorder. Finally, new methods and models relevant to bipolar disorder, including stem cells and genetically modified mice, are being used to study key pathways and drug effects. A combination of these approaches has real potential to break the impasse and deliver genuinely new treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available